Invex Reports $4.5M Cash and Reduced Operating Outflows in Q3 FY26
Invex Therapeutics reported promising preclinical findings on Exenatide’s effects in a human Alzheimer's disease model, alongside a steady cash position and reduced operating outflows in Q3 FY26.
- Exenatide reduces neurofilament light chain and inflammatory cytokines in ADBrain™ model
- Cash reserves slightly down to $4.5 million with operating outflows easing
- Company secretary resigns amid ongoing corporate restructuring
- Further investigation planned on amyloid beta effects in preclinical studies
- Expanded collaboration with Tessara Therapeutics continues to shape R&D focus
Preclinical Data Highlights Neuroprotective Signals
Invex Therapeutics (ASX:IXC) has revealed encouraging new data from its collaboration with Tessara Therapeutics, showing that Exenatide significantly lowers markers linked to neuronal stress and inflammation in Tessara’s human iPSC-derived ADBrain™ model of Alzheimer's disease. Notably, Exenatide reduced secreted neurofilament light chain (Nf-L) levels by around 40%, a biomarker associated with early neurodegeneration, while also dampening pro-inflammatory cytokines IL-6 and IL-8, which play a role in neuroinflammation common to Alzheimer's pathology.
These findings suggest Exenatide could exert therapeutic benefits early in disease progression, reinforcing its potential beyond raised intracranial pressure indications. However, the observed 35% reduction in amyloid beta (AB) burden at higher Exenatide concentrations requires further scrutiny due to concurrent increases in GAPDH, a housekeeping protein used for normalization, indicating complexities in interpreting these effects.
Operational and Corporate Developments
The quarter saw Invex initiate an expanded preclinical program with Tessara, including evaluation of GLP-1 receptor agonists Exenatide and Dulaglutide in novel combination regimens within the ADBrain™ model. This builds on prior promising results and aligns with Invex’s strategy to broaden its intellectual property portfolio for neurological conditions linked to raised intracranial pressure.
On the corporate front, Invex held its deferred Annual General Meeting in February and announced the resignation of Joint Company Secretary Carla Healy in late March. These changes follow a series of board and executive reshuffles earlier in the year, which have been part of the company’s governance reset after a trading suspension was lifted in late 2025. The company’s ongoing R&D momentum and cash management were highlighted in recent coverage detailing board reshuffles and $4.5M cash reserve.
Financial Position and Cash Flow
Invex finished the quarter with $4.517 million in cash and equivalents, down slightly from $4.595 million at the end of Q2 FY26. Operating cash outflows narrowed significantly to $79,000 from $430,000 the previous quarter, reflecting reduced administration and corporate costs after one-off expenses related to director and company secretary departures were recognised in Q2.
Research and development spending rose modestly to $53,000, primarily driven by payments for the ongoing analysis of Exenatide in the ADBrain™ model. Related party payments, including director fees and consulting, amounted to $70,000 for the quarter. No financing activities were reported, and the company maintains no debt facilities.
Bottom Line?
Invex’s latest preclinical findings bolster Exenatide’s potential in neurodegenerative disease, but the path to clinical validation remains complex and closely tied to ongoing R&D progress and cash management.
Questions in the middle?
- Will further investigation clarify Exenatide’s impact on amyloid beta dynamics in Alzheimer’s models?
- How will corporate changes, including the company secretary resignation, affect operational continuity?
- What are the timelines and milestones for translating these preclinical signals into clinical development?
